Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 18;12:1758835920980546. doi: 10.1177/1758835920980546

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2020

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Combined analysis of prognostic effect of any immune-related adverse events (irAEs) versus no irAEs on progression-free survival (PFS) and efficacy in cancer patients treated with immune checkpoint inhibitors. A, The association between irAEs and PFS; B, Assessing the association between irAEs and PFS based on landmark analysis results; C, Objective response rates in cancer patients with or without irAEs when treated with immune checkpoint inhibitors. Subgroup analysis was performed with regard to cancer types (non-small-cell lung carcinoma, melanoma, and other cancers).